Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities (2021 - 2025)

Amylyx Pharmaceuticals has reported Cash from Financing Activities over the past 5 years, most recently at -$208000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 289.09% year-over-year to -$208000.0; the TTM value through Dec 2025 reached $257.0 million, up 73758.91%, while the annual FY2025 figure was $257.0 million, 73758.91% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$208000.0 at Amylyx Pharmaceuticals, down from $191.6 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $232.2 million in Q4 2022 and troughed at -$1.1 million in Q4 2021.
  • A 5-year average of $44.8 million and a median of $889000.0 in 2023 define the central range for Cash from Financing Activities.
  • On a YoY basis, Cash from Financing Activities climbed as much as 239407.5% in 2025 and fell as far as 289.09% in 2025.
  • Year by year, Cash from Financing Activities stood at -$1.1 million in 2021, then soared by 21899.25% to $232.2 million in 2022, then plummeted by 99.9% to $230000.0 in 2023, then tumbled by 52.17% to $110000.0 in 2024, then crashed by 289.09% to -$208000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for AMLX at -$208000.0 in Q4 2025, $191.6 million in Q3 2025, and -$31000.0 in Q2 2025.